Szemészet, 2020 (157. évfolyam, 1-4. szám)

2020-03-01 / 1. szám

Okuláris toxoplasmosis diagnosztikája és kezelése Irodalom 1. Atmaca LS, Simsek T, Batioglu F Clinical features and prognosis in ocular toxoplasmosis. Jpn J Ophthalmolm 2004 Jul-Aug; 48(4): 386-91. 2. Basu S, Biswas J, Pleyer U, Pathangay A, Manohar Bábu B. An ophthalmologist survey-based study of the atypical presentations and current treatment practices of ocular toxoplasmosis in India. J Parasit Dis 2011 Oct; 35(2): 148-54. 3. Feliciano-Alfonso JE, Vargas-Villanueva A, Marín MA, et al. Antibiotic treatment for ocular toxoplasmosis: a systematic review and meta­analysis: study protocol. Syst Rev 2019 Jun 20; 8(1): 146. 4. Garweg JG, de Groot-Mijnes JD, Montoya JG. Diagnostic Approach to Ocular Toxoplasmosis. Ocul Immunol Inflamm 2011 Aug; 19(4): 255-261. 5. Harper TW, Miller D, Schiffman JC, Davis JL. Polymerase chain reaction analysis of aqueous and vitreous specimens in the diagnosis of posterior segment infectious uveitis. Am J Ophthalmol 2009 Jan; 147(1): 140-147. 6. Heringer GO, Oueghlani E, Dell'ümo R, Curi AL, Oréfice F Pavésio CE. Risk of reactivation of toxoplasmic retinitis following intraocular procedures without the use of prophylactic therapy. Br J Ophthalmol 2014 Sep; 98(9): 1218-20. 7. Holland GN, Lewis KG. An update on current practices in the manage­ment of ocular toxoplasmosis. Am J Ophthalmol 2002 Jul; 134(1): 102-14. 8. Mathis T, Beccat S, Séve R Peyron F Wallon M, Kodjikian L. Comparison of immunoblotting (IgA and IgG) and the Goldmann- Witmer coefficient for diagnosis of ocular toxoplasmosis in immunocompetent patients. Br J Ophthalmol. 2018 Oct; 102(10): 1454-1458. 9. Marcolino PT, Silva DA, Leser PG, Camargo ME, Mineo JR. Molecular markers in acute and chronic phases of human toxoplasmosis: determination of immunoglobulin G avidity by Western blotting. Clin Diagn Lab Immunol 2000 May; 7(3): 384-9. 10. Orefice F Bahia-Oliveira LM. Toxoplasmose. In: Orefice F Uveite clinica e cirúrgica. Rio De Janeiro: Cultura Médica 2005: 699-804. 11. Pradhan E, Bhandari S, Gilbert RE, Stanford M. Antibiotics versus no treatment for toxoplasma retinochoroiditis. Cochrane Database Syst Rev 2016 May 20; 5. 12. Read RW, et al. Infectious Ocular Inflammatory Diseases. Basic and clinical science course (BCSC! Section 9: Intraocular Inflammation and Uveitis. San Francisco, CA: American Academy of Ophthalmology 2018-2019;193-204. 13. Reich M, Mackensen F. Ocular toxoplasmosis: background and evidence for an antibiotic prophylaxis. Curr Opin Ophthalmol 2015 Nov; 26(6): 498-505. 14. Robert-Gangneux F Dardé ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev 2012; 25: 264-296. 15. Soheilian M, Sadoughi MM, Ghajarnia M, Dehghan MH, Yazdani S, Behboudi H, Anisian A, Peyman GA. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 2005 Nov; 112(11): 1876-82. 16. Suzuki LA, Rocha RJ, Rossi CL. Evaluation of serological markers for the immunodiagnosis of acute acquired toxoplasmosis. J Med Microbiol 2001; 50: 62-70. — Levelezési cím ___________________________ Dr. Hadarits Flóra, B720 Szeged, Korányi fasor 10-11. E-mail cím: hadarits.flora@med.u-szeged.hu Vivinex iSert Előretöltött injektor rendszer | Hidrofób akril műlencse PÉLDÁTLAN LATASELESSEG HOYA SURGICAL OPTICS — Vivinex' MODEL XC1 I MODEL XY1 ^ UP

Next

/
  • Layout
  • Zoom
  • Rotation
Thumbnails
Contents